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Objective	The	role	of	exercise	in	the	prevention	and	treatment	of	chronic	diseases	is	widely	accepted	and	regular	physical	exercise	may	play	an	 irreplaceable	role	beyond	traditional	medicine	and	drug	treatments.	 However,	 	current	 guidelines	 do	 not	 provide	 details	 on	 the	 characteristics	 of	 exercise	programs	which	are	aimed	to	be	carried	out	concomitantly	to	drug	treatments.	Moroever,	the	safety	of	combined	exercise	and	drug	treatments	has	rarely	been	considered.	The	future	of	exercise	is	medicine	research	will	likely	need	to	focus	on	questions	such	as	how	to	build	customized	 exercise	 programs	 for	 different	 patients	 in	 the	 context	 of	 individual	 physiological	responses	to	exercise?	When	combining	drug	and	concomitant	exercise	treatment,	what	is	the	optimal	exercise	prescription	in	terms	of	timing,	intensity	and	duration?	Does	exercise	only	have	an	additive	effect	or	may	exercise	actually	reverse	or	even	cancel	out	some	of	the	expected	effects	induced	by	the	drug	 treatment?		What	 is	 the	role	of	diet	 in	exercise	 interventions?	Does	a	given	exercise	program	affect	the	lipid	and	glucose	metabolism	to	the	same	extent?	In	this	report,	we	will	present	different	randomized	clinical	trials	conducted	in	our	research	group	to	tackle	some	of	the	abovementioned	questions.	This	particularly	 includes	patients	with	comorbidity	conditions	(prediabetes	and	non-alcohol	 fatty	 liver	disease,NAFLD),	as	well	as	patients	with	type	2	diabetes	(T2D).	
Methods	 Two	 different	 randomized	 trials	 are	 included,	 both	 of	 which	 were	 conducted	 in	 China	(ChiCTR-IOR-16008469	and	ISRCTN	42622771).	The	ChiCTR-IOR-16008469	study	was	a	randomized	crossover	 trial.	 The	 aim	 of	 this	 study	 was	 to	 assess	 whether	 the	 duration	 between	 metformin	administration	 and	 high-intensity	 cycling	 (HIIT)	 affects	 the	 glucose	 metabolism.	 T2D	 patients	performed	a	single	session	of		HIIT	(~25	minutes)	at	30	(EX30),	60	(EX60),	and	90	(EX90)	minutes	following	breakfast	and	metformin	administration	in	a	randomized	order.	Subjects’	diurnal	glucose	metabolism	was	assessed	between	8:00	a.m.	and	4:00	p.m.	(Metf)	of	each	exercise	day	as	well	as	on	a	control	day.	Furthermore,	insulin	was	assessed	both	before	and	immediately	after	each	exercise	bout.	The	 ISRCTN42622771	 trial	was	a	 four	arm	randomized	 trial.	 Six-hundred	and	 three	patients	 from	seven	 clinics	 were	 recruited,	 out	 of	 which	 115	 individuals	 aged	 50-65-year	 fulfilled	 the	 inclusion	criteria	 (impaired	 fasting	glucose	(IFG)	or	 impaired	glucose	 tolerance	(IGT)	and	NAFLD)	and	were	randomly	 assigned	 (1:1:1:1)	 to	 either	 of	 the	 four	 groups:	 aerobic	 exercise	 (AEx,	 n	 =	 29),	 diet	intervention	(Diet,	n	=	28),	aerobic	exercise	plus	diet	intervention	(AED	=	29),	or	no	intervention	(NI	=	29).	The	study	spanned	over	anaverage	period	of	8.6	months	(7-11	months).	Progressive	supervised	aerobic	exercise	training	(60-75%	intensity)	was	carried	out	2-3	times/week	in	30-60	min/sessions,	and	the	diet	intervention	consisted	of	a	lunch	with	38%	carbohydrate	and	diet	fibre	of	12g	per	day,	while	the	remaining	meals	were	freely	chosen	but	with	supervised	nutrition	intakes.	The	hepatic	fat	content	 (HFC)	 assessed	 by	 1H	 MRS,	 glycated	 haemoglobin	 (HbA1c)	 and	 insulin	 sensitivity	 were	assessed	by	conventional	methods.	
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Results	 In	 study	 1,	 we	 found	 that	 in	 diabetes	 patient	 glucose	 levels	 significantly	 decreased	 in	 all	exercise	settings,	irrespective	of	the	timing.		However,	whenHIIT	was	performed	at	30	minutes	post-metformin	administration,	the	peak	glucose	was	lowered,	thereby	further	stabilizing	the	postprandial	glucose	 fluctuation.	 The	 risk	 for	 hypoglycemia	 at	 different	 times	 to	 exercise	 after	 metformin	administration	was	highest	in	EX90	(22.2%)	compared	to	EX30	(3.7%)	and	EX60	(7.4%).	While	the	lactate	 level	was	 19%	higher	 in	 EX60	 and	 8%	higher	 in	 EX90	 compared	 to	 EX30.	 Compared	with	Metformin,	the	decrease	in	insulin	was	larger	in	EX30	and	EX60	(both	p	<	0	001).	These	results	indicate	that	 timing	of	exercise	 is	an	 important	 factor	 to	consider	when	prescribing	exercise	as	adjuvant	 to	metformin	therapy	for	T2DM	patients.	In	study	2,	we	showed	that	in	patients	with	morbidity	(prediabetes	with	NAFLD),	HFC	was	significantly	reduced	 in	 the	AEx	 (–24.4%),	 diet	 (–23.2%),	 and	AED	 (–47.9%)	 groups,	 as	 opposed	 to	 the	 20.9%	increase	in	the	NI	group	(p=0.006,	p=0.002,	and	P<0.0001,	respectively).Importantly,	HFC	decreased	to	normal	levels	(<5.6%)	in	ten	(44%)	out	of	23	participants	in	the	exercise	plus	diet	group	and	nine	(41%)	out	of	22	participants	in	the	diet	group,	while	the	in	the	exercise	group	it	decreased	only	in	three	(14%)	out	of	29		participants.	Further,	all	intervention	groups	showed	improvements	ininsulin	sensitivity	(AEx	33%,	p=0.023,	Diet	37%,	p=0.012,	and	AED	34%,	p=0.029)	but	only	the	AED	group	significantly	 decreased	 HbA1c	 (-4.4%,	 p=0.01)	 compared	 with	 the	 NI	 group	 (1.9%	 and	 -0.6%).	However,	after	controlling	for	the	change	of	body	weight	as	well	as	for	the	duration	of	the	intervention	and	baseline	values,	 the	significant	differences	 in	HbA1cand	insulin	sensitivity	between	the	groups	disappeared.	Furthermore,	based	on	HbA1c	IFG	or	IGT,	no	significant	remission	and	progression	from	prediabetes	to	diabetes	were	observed	between	the	intervention	and	NI.	
Conclusions	The	results	derived	from	these	two	trials	imply	that:	1)	the	combined	effects	of	exercise	and	metformin	therapy	on	T2D	should	take	into	account	that	both	exercise	and	metformin	are	likely	to	affect	the	lactic	metabolism	because	T2D	is	considered	as	a	redox	disease.	For	the	acute	effect	of	exercise	combined	with	metformin	therapy,	exercising	at	30	minutes	post-metformin	administration	appeared	 to	 be	 optimal	 for	 reducing	 glucose	 fluctuation.	 To	 avoid	 the	 risk	 for	 hypoglycemia	 and	lactases	 with	 the	 combined	 treatment,	 selecting	 optimal	 timing	may	 be	 the	 first	 and	 easiest	 step	towards	personalized	exercise	medicine.	Thus,	when	exercise	is	recommended	to	diabetic	patients,	the	timing	of	exercise	may	be	an	important	consideration	so	that	the	therapeutic	effects	of	metformin	are	not	compromised.	However,	 further	studies	are	warranted	to	elucidate	the	 long-term	effects	of	combining	metformin	and	exercise	on	glycemic	control	and	lactic	metabolism	as	well	as	the	underlying	mechanisms.	2)	Aerobic	 exercise	 training	 combined	with	a	 fibre-enriched	diet	 can	aid	 reduce	HFC	more	 effectively	 than	 either	 exercise	 or	 increased	 fibre	 intake	 alone	 in	 pre-diabetic	 patients	with	NAFLD.	However,	the	effect	on	glycaemic	control	and	insulin	sensitivity	is	not	substantial.	Therefore,	it	remains	to	be	addressed	why	the	same	intervention	protocol	did	not	show	the	similar	effect	on	the	HFC	 and	 glycaemic	 control/insulin	 sensitivity	 in	 the	 same	 subjects.	 When	 these	 questions	 being	uncovered,	the	combined	intervention	could	be	considered	as	an	integral	part	of	lifestyle	interventions	for	patients	with	a	cordiality	condition	for	an	increased	risk	of	developing	T2D.	
